| Summary: | In some countries such as the United States, kidney disease kills more people than cancers of the prostate or breast. In the United States for example there are over 15 million individuals with kidney disease. Translated to a worldwide basis, kidney disease of various aetiologies represent a significant burden on healthcare systems, affecting mortality, morbidity and also the family unit. It is therefore imperative that appropriate use is made of conventional, new and emerging biomarker platforms to aid diagnosis, treatment and an understanding of outcome measures. Biomarkers in Kidney Disease embraces a holistic approach by combining information on different conditions that affect the kidney and the use of biomarkers. Biomarkers are described in terms of conventional, new and emerging analytes, techniques, platforms and applications. It covers the latest knowledge and trends. New platforms are described which combine advances in biomedical sciences, physics, computing and chemistry.
|
|---|